Health Innovation
5 Nordic Health Startups Moving From Research to Market
DealBio tracks early-stage health startups across Europe and North America. These 5 Nordic startups show how research-led health innovation moves from academic evidence into products that must work in clinics, laboratories and advanced-therapy development.
- Nordics
- Research Translation
- Medtech
- Diagnostics
- Biotech
DealBio tracks early-stage health startups across Europe and North America. These 5 Nordic startups show how research-led health innovation moves from academic evidence into products that must work in clinics, laboratories and advanced-therapy development.
The common thread is translation risk. EpiMass and Bioelectrix start from technical evidence that has to become usable hardware. Equilibrium Diagnostics is turning kidney physiology into a practical risk signal. Heureka Therapeutics and Ibnova Therapeutics are moving disease biology and tissue engineering toward drug and cell-therapy development.
That makes this article less about a single Nordic sector and more about the handoff from research to execution. The startups that stand out are not just scientifically interesting; they have to show that the evidence can support a workflow, a manufacturable product and a financing path beyond the lab.
At a Glance
- EpiMassDenmark2026Real-time tissue analysis for skin cancer surgery
- BioelectrixSweden2025Electrical wound electrodes
- Equilibrium DiagnosticsDenmark2026Urine-based kidney progression risk
- Heureka TherapeuticsDenmark2026Liver-targeted metabolic-disease therapeutics
- Ibnova TherapeuticsDenmark2026Engineered heart-muscle patches
01
EpiMass
Developing real-time tissue analysis to guide skin cancer surgery.
- Country
Denmark- Founded
- 2026
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why EpiMass stands out
BioInnovation Institute selected EpiMass for its September 2026 cohort, providing a €560,000 convertible loan and business-development support.
Founder-led research used MALDI imaging and machine learning on 25 mouse skin-tumour sections, reporting 92.3% cross-validation accuracy in a 2024 study.
What EpiMass is building
EpiMass is developing a platform that captures material released during laser removal of skin tissue. Mass spectrometry reads the tissue chemistry while machine learning is intended to distinguish tumour from surrounding tissue.
The product addresses a practical limitation of laser treatment: tissue is destroyed during removal, making conventional margin examination harder.
Developing electrical wound electrodes to accelerate healing of diabetic foot ulcers.
- Country
Sweden- Founded
- 2025
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Bioelectrix stands out
Bioelectrix’s founders co-authored a 2023 study in which direct current increased wound-gap closure nearly threefold in healthy and diabetic-like skin-cell models versus unstimulated controls.
The startup is the applicant on an international wound-dressing patent application published in February 2026 and has backing from Chalmers Ventures.
What Bioelectrix is building
Bioelectrix is developing electrodes that apply a controlled electrical field to guide skin cells across chronic wounds, starting with diabetic foot ulcers.
Later versions are intended to add wound measurements such as impedance, acidity and temperature alongside active electrical stimulation.
Developing a urine test to assess kidney function and predict disease progression.
- Country
- Denmark
- Founded
- 2026
- Sector
- Diagnostics
- Funding stage
- Seed or earlier
Why Equilibrium Diagnostics stands out
Equilibrium Diagnostics joined BioInnovation Institute Venture Lab with DKK 4.2 million in convertible financing and 12 months of venture-building support.
Its urine Ammonium-pH Index has shown prognostic value across multiple kidney-disease cohorts and adds information beyond standard kidney-risk models.
What Equilibrium Diagnostics is building
The AP Reader measures urinary ammonium and pH from one sample, and software combines them into a score for kidney tubular acid-handling function.
The near-term use is risk stratification: identifying chronic-kidney-disease patients who may need closer monitoring or earlier specialist care.
Developing targeted therapies for metabolic liver disease.
- Country
- Denmark
- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Heureka Therapeutics stands out
Heureka joined BioInnovation Institute Venture Lab in March 2026, gaining 12 months of company-building support and €500,000 in convertible funding.
The startup builds on liver-targeted peptide-drug conjugates designed to deliver AMPK activators into liver cells while limiting systemic exposure.
What Heureka Therapeutics is building
Heureka Therapeutics is developing targeted therapies for MASLD and MASH, metabolic liver diseases linked to fat accumulation, inflammation and scarring.
Its early programme aims to improve liver fat metabolism through liver-directed delivery rather than broad systemic exposure.
Developing vascularized heart muscle patches to treat heart failure.
- Country
- Denmark
- Founded
- 2026
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Ibnova Therapeutics stands out
Ibnova Therapeutics joined BioInnovation Institute Venture Lab with up to €500,000 in convertible financing, laboratory space and venture support.
Its founding research restored heart function in animal models, while co-founder James Hudson contributed to earlier cardiac-patch work that reached a Phase 1/2 trial.
What Ibnova Therapeutics is building
Ibnova grows vascularized human heart-muscle patches from stem cells. The patch combines cardiomyocytes with vascular cells and is designed to be attached over damaged myocardium after a heart attack.
The intended product is allogeneic, meaning made from donor cells for use in multiple patients, and available off the shelf.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The investor signal in this Nordic group is the quality of the bridge from research to product. Academic origin can create technical depth, but it does not automatically create a startup. The stronger cases are those where evidence, clinical use and venture-building support are already pointing toward a specific product path.
For investors, the next diligence question is whether each startup can compress translation time without losing clinical relevance. The useful milestones will be practical: stronger validation, clearer manufacturing assumptions, defined clinical settings and evidence that the product can leave the research environment without becoming too complex to adopt.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on Denmark- and Sweden-based businesses with published DealBio Startup Briefs and clear research-to-market relevance. The selection emphasizes distinct clinical areas and avoids overconcentrating the article around a single accelerator or technology type. DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.